Comparing the effect of Metformin and Megestrol acetate on endometrial histology in patients with disordered proliferative or hyperplastic endometrium. A RCT

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201205265283N4

Enrollment

Registered

2013-03-16

Start date

2011-12-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with abnormal uterine bleeding and have disordered proliferative or hyperplastic endometrium with or without atypia. Endometrial glandular hyperplasia

Interventions

Intervention 1: First group: fifteen cases with disordered proliferative endometrium , 15 cases with hyperplastic atypical endometrium and 15 cases with hyperplasticendometrium and without atypia who

Treatment - Drugs

First group: fifteen cases with disordered proliferative endometrium , 15 cases with hyperplastic atypical endometrium and 15 cases with hyperplasticendometrium and without atypia who referred to Al

Second group: fifteen cases with disordered proliferative endometrium , 15 cases with hyperplastic atypical endometrium and 15 cases with hyperplastic endometrium and without atypia who referred to

Eligibility

Sex/Gender

Female

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with abnormal uterine bleeding and havingdisordered proliferative or hyperplastic endometrium with or without atypia. Consent to participate. Exclusion criteria: Patients who have allergy to metformin, Patients with renal failure, nausea, vomiting, anorexia, anemia, cutaneous lesionsor not satisfied to participate in the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Endometrialpathology. Timepoint: before surgery. Method of measurement: Pathologic assessment.;Endometrial Histologic type. Timepoint: Three months after medical therapy. Method of measurement: Microscopic assessment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactManizheh Sayyah-Melli

Tabriz University of Medical Sciences

manizheh.sayyahmelli@gmail.com+98 41 1553 9161

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026